a2a receptor antagonists: potential adjuvant therapies for levodopa optimisation
Published 4 years ago • 1.1K plays • Length 30:29Download video MP4
Download video MP3
Similar videos
-
6:30
pharmacology - parkinson's disease
-
5:11
bridging the dopamine gap with nourianz | pd medications, purposes, and mechanisms #3
-
2:01
levodopa carbidopa combination for parkinsonism
-
4:36
a2a antagonist improves dopaminergic function and reduces neuroinflammation in a rodent model of pd
-
38:05
parkinson's medications - part 1: levodopa
-
6:18
my parkinson's body & timing when to take levodopa/carbidopa
-
5:54
dr. karunapuzha on how to take levodopa for parkinson's and why
-
6:24
neurologist's tips for taking sinemet
-
7:07
optimizing levodopa-carbidopa intestinal gel dosing in parkinson's
-
2:11
the parkinson's minute: gel formulation of levodopa-carbidopa
-
3:42
pharmacology [cns] 3- parkinson's disease treatment [part 1: levodopa carbidopa and benserazide ]
-
2:35
levodopa dose adjustment versus adjunctive therapy in parkinson’s disease
-
42:34
parkinson's medications - part 2: dopamine agonists, mao-b inhibitors, and more
-
13:47
dopamine receptor agonists for parkinson disease (pd)
-
4:37
parkinson’s pharmacology - neurology
-
2:00
adjunctive mao-b or comt inhibitors to optimize levodopa treatment in pd
-
4:19
kyowa kirin's nourianz (istradefylline): a fda approved new drug for parkinson’s disease treatment
-
3:06
pharmacology [cns] 4- parkinson's disease treatment [ 2: bromocriptine - apomorphine - pramipexole ]
-
1:13
extending the efficacy of levodopa in patients with parkinson’s disease
-
3:32
adequately treating parkinson disease with levodopa
-
2:05:04
medications and therapies for pd